基于HBV感染自然病程的慢性乙型肝炎患者外周血白细胞 介素-35表达水平及与病毒载量和转氨酶的相关性

doi:10.19871/j.cnki.xfcrbzz.2023.02.002

摘要/Abstract

摘要： 目的探究白细胞介素-35（IL-35）在慢性HBV感染自然病程中的表达及与病毒载量和肝脏生化指标的相关性,评估其在HBV慢性感染管理中的作用,为动态监测慢性乙型肝炎（简称乙肝）病程并降低重症化提供证据。方法选取2015年1月至2020年11月上海长海医院感染科就诊的慢性HBV感染者83例,依据慢性HBV感染的自然病程分为免疫耐受期22例、免疫清除期29例及重型肝炎32例。选取健康对照20例。空腹采取患者静脉血,应用酶联免疫吸附试验（ELISA）检测外周血IL-35表达水平,同时检测HBV DNA及转氨酶水平。统计学方法采用两组间Mann-Whitney U检验、多组间Kruskal-Wallis H检验以及相关性分析。结果慢性HBV感染者与健康对照者的IL-35分别为51.75（9.9,96.5）pg/ml和7.33（3.35,8.76）pg/ml,差异有统计学意义（Z=-5.69,P<0.01）。慢性HBV感染后各自然病程中IL-35表达水平均高于健康对照组,其中在重型肝炎患者中表达最高,为121.46（68.98,213.44）pg/ml。IL-35指标变化与HBV DNA无明显相关性（r分别为0.385、0.392、-0.168,P均>0.05）。重型肝炎患者的IL-35与ALT呈正相关（ρ=0.543,P=0.045）,慢性HBV感染后整体IL-35与ALT和AST均呈较好的正相关（ALT：r=0.684,P=0.001;AST：r=0.618,P=0.001）。血清IL-35每增加1个单位,进展至重型肝炎的可能性增加7.2%。血清IL-35水平的ROC曲线显示AUC为0.9491（95%CI：0.9078~0.9905,P<0.01）,cut off值<50.95pg/ml。结论 ①HBV慢性感染病程中外周血高表达IL-35,IL-35水平同肝脏炎症程度呈正相关;②IL-35在临床评估乙肝患者病情方面有重要应用价值,可动态监测外周血IL-35水平辅助评估患者免疫状态,及早抗病毒治疗以降低重型肝炎的发生率。

关键词: 乙型肝炎病毒, 慢性乙型肝炎, 自然病程, 白细胞介素-35, 重型肝炎

Abstract: Objective To investigate the expression of interleukin-35 (IL-35) in the natural course of chronic HBV infection and its correlation with viral load and liver biochemical parameters, and to evaluate its role in the management of chronic HBV infection so as to provide evidence for dynamic monitoring of the course of disease and reducing severity. Method 83 patients with chronic HBV infection were selected from the Department of Infectious Diseases of Shanghai Changhai Hospital from January 2015 to November 2020, including immune tolerance group (n=22), immune clearance group (n=29) and severe hepatitis group (n=32) according to the natural course of chronic HBV infection. 20 healthy people were chosen as control. The expression level of IL-35 in peripheral blood was detected by ELISA (enzyme linked immunosorbent assay), HBV DNA and transaminase were also detected meanwhile. Statistical analysis was performed using the Mann-Whitney U test between two groups, Kruskal-Wallis H test between multiple groups and correlation analysis. Result The IL-35 levels of chronic HBV infection and healthy people were 51.75 (9.9,96.5)pg/ml and 7.33 (3.35,8.76) pg/ml respectively, the difference was statistically significant (Z=-5.69, P<0.01). The natural course of chronic HBV infection was higher than that in healthy controls, and IL-35 expression was highest in severe hepatitis group [121.46 (68.98,213.44) pg/ml]. There was no significant correlation between IL-35 and HBV DNA (r=0.385, 0.392, -0.168, P>0.05). There was positive correlation between IL-35 and ALT in patients with severe hepatitis (ρ=0.543, P=0.045), and a good positive correlation between IL-35 and ALT or AST in patients with chronic HBV infection (ALT: r=0.684, P=0.001; AST: r=0.618, P=0.001). For each unit increase in serum IL-35, the likelihood of progression to severe hepatitis increased by 7.2%. The ROC curve of serum IL-35 level showed AUC was 0.9491 (95%CI: 0.9078-0.9905, P<0.01), cut off <50.95 pg/ml. Conclusion ①IL-35 is highly expressed in peripheral blood in the course of HBV chronic infection and is positively correlated with the degree of liver inflammation; ②IL-35 has important application value in clinical evaluation of hepatitis B patients. Dynamic monitoring of IL-35 level in peripheral blood can assist in evaluating patients’ immune status, and early antiviral treatment can reduce the incidence of severe hepatitis.

Key words: Hepatitis B virus, Chronic hepatitis B, Natural course of CHB, Interleukin-35, Severe hepatitis

中图分类号:

R512.6

董旭, 刘亚允, 朱彤, 徐爱静, 薛建亚, 梁雪松. 基于HBV感染自然病程的慢性乙型肝炎患者外周血白细胞介素-35表达水平及与病毒载量和转氨酶的相关性[J]. 新发传染病电子杂志, 2023, 8(2): 8-12.

Dong Xu, Liu Yayun, Zhu Tong, Xu Aijing, Xue Jianya, Liang Xuesong. Interleukin-35 expression in peripheral blood and its correlation with viral load and transaminase in patients with chronic hepatitis B based on the natural course of HBV infection[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(2): 8-12.

参考文献

[1] POLARIS OBSERVATORY COLLABORATORS.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403.
[2] LEE HM, BANINI BA.Updates on Chronic HBV: Current Challenges and Future Goals[J]. Curr Treat Options Gastroenterol, 2019, 17(2): 271-291.
[3] 易永祥. 乙型肝炎病毒的分子流行病学研究进展[J/CD]. 新发传染病电子杂志, 2020, 5(1): 1-7.
[4] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J/CD]. 中国医学前沿杂志(电子版),2019, 11(12):51-77.
[5] LI X, LIU X, WANG W.IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases [J/CD]. Front Cell Dev Biol, 2021, 9: 614847.
[6] XIANG XG, XIE Q.IL-35: a potential therapeutic target for controlling hepatitis B virus infection[J]. J Dig Dis, 2015, 16(1): 1-6.
[7] LIANG XS, LI C Z, ZHOU Y, et al.Changes in circulating Foxp3(+) regulatory T cells and interleukin-17-producing T helper cells during HBV-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2014, 20(26): 8558-8571.
[8] CATALáN D, MANSILLA MA, FERRIER A, et al. Immunosuppressive Mechanisms of Regulatory B Cells [J/CD]. Front Immunol, 2021, 12: 611795.
[9] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J/CD].中国肝脏病杂志(电子版), 2015, 7(3):1-18.
[10] EGWUAGU CE, YU CR, SUN L, et al.Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases[J]. Cytokine Growth Factor Rev, 2015, 26(5): 587-593.
[11] 王宇航, 王为光, 赵悦荣, 等. IL-17和IL-35与多种疾病之间的研究进展[J]. 中国医学创新, 2021, 18(14): 180-184.
[12] IANNACONE M, GUIDOTTI L G.Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2022, 22(1): 19-32.
[13] RIBEIRO CRA, BEGHINI DG, LEMOS AS, et al.Cytokines profile in patients with acute and chronic hepatitis B infection[J]. Microbiol Immunol, 2022, 66(1): 31-39.
[14] XIA Y, PROTZER U.Control of Hepatitis B Virus by Cytokines[J]. Viruses, 2017, 9(1): 18.
[15] 杜立树, 平龙玉, 张曼俐. 细胞因子在乙肝相关性肝衰竭患者中的表达意义[J]. 中国中西医结合消化杂志, 2017, 25(2): 144-147.
[16] 刘亚允, 余娇, 杨阳, 等. 慢性乙型肝炎患者外周血分泌白细胞介素-35的B细胞和白细胞介素-35表达水平及其意义[J]. 中华传染病杂志, 2017, 35(9): 528-532.
[17] SHI YY, DAI MJ, WU GP, et al.Levels of interleukin-35 and its relationship with regulatory T-cells in chronic hepatitis B patients[J]. Viral Immunol, 2015, 28(2): 93-100.
[18] HU S, LIAN PP, HU Y, et al.The Role of IL-35 in the Pathophysiological Processes of Liver Disease [J/CD]. Front Pharmacol, 2020, 11: 569575.
[19] 陈丽, 罗二平, 黄小平, 等. 乙型慢加亚急性肝衰竭患者血清白细胞介素-35的表达及其临床意义[J]. 实用医学杂志, 2013, 29(17): 2800-2802.
[20] CHEN L, SUN W, WANG Y, et al.Lower levels of interleukin-35 in patients with prophase of liver failure are associated with progression to liver failure[J]. Ann Palliat Med, 2021, 10(8): 9174-9183.
[21] TENG DK, LIU Y, LV YF, et al.Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection[J]. Int Immunopharmacol, 2019, 70: 252-259.
[22] 邓昭敏, 刘琳, 熊颖妮, 等. IL-35在慢性乙型肝炎发病过程中的免疫抑制作用[J]. 国际检验医学杂志, 2018, 39(19): 2376-2378+2382.
[23] 高艺, 梁志军, 符健. IL-35对慢加急性肝衰竭患者外周血CD8+ T淋巴细胞功能的影响[J]. 临床肝胆病杂志, 2019, 35(9): 2011-2016.
[24] TANG Y, MA T, JIA S, et al.The Mechanism of Interleukin-35 in Chronic Hepatitis B[J]. Semin Liver Dis, 2021, 41(4): 516-524.
[25] 高夕雷, 张雷鸣, 于建秀, 等. 慢性乙型肝炎患者血清IL-35与肝纤维指标相关性分析[J]. 江苏预防医学, 2020, 31(1): 29-32.
[26] 詹爱琴, 陈春丽, 安轶, 等. 恩替卡韦对慢性乙型肝炎患者Treg/Th17细胞平衡及相关细胞因子水平的影响分析[J]. 新疆医学, 2020, 50(9): 906-909.
[27] 刘红, 徐瑞芳. 富马酸替诺福韦二吡呋酯片治疗慢性乙肝对患者肝功能及外周血IL-35表达的影响[J]. 海南医学, 2020, 31(8): 980-982.
[28] ZHONG S, ZHANG T, TANG L, et al.Cytokines and Chemokines in HBV Infection[J/CD]. Front Mol Biosci, 2021, 8: 805625.